Debugging a cancer therapy
Sergio Gonz ález Rubio, Nuria Montero Pastor, Carolina García, Víctor G. Almendro-Vedia, Irene Ferrer, Paolo Natale, Luis Paz-Ares, M. Pilar Lillo, Iván López-Montero
Conclusion: Collectively, our data indicated that PepE may represent a promising therapeutic lead compound for intervention in gastric cancer metastasis and may also exhibit potential as a DNA methylation inhibitor for use in epigenetic cancer therapy.Cell Physiol Biochem 2018;50:2341 –2364
This article is protected by copyright. All rights reserved.
Publication date: 1 February 2019Source: Colloids and Surfaces B: Biointerfaces, Volume 174Author(s): Pradip Das, Miriam Colombo, Davide ProsperiAbstractRecently, magnetic fluid hyperthermia using biocompatible magnetic nanoparticles as heat mediators for cancer therapy has been extensively investigated due to its high efficiency and limited side effects. However, the development of more efficient heat nanomediators that exhibit very high specific absorption rate (SAR) value is essential for clinical application to overcome the several restrictions previously encountered due to the large quantity of nanomaterial required f...
Researchers from The University of Texas MD Anderson Cancer Center found that the nauseating procedure resolved severe colitis in two patients who developed the disease following cancer therapy.
Conclusion: Propolis extracts may be important economically, allowing a relatively inexpensive cancer treatment associated to lower concentrations of drugs. In this review, the activity and mechanisms of action of propolis and CAPE on breast cancer cells are discussed.
Conclusion: The ethanol ADH acetaldehyde system offers a simple, safe, non-toxic approach to cancer therapy prodrug toxin technology. It may also offer a safe and non-toxic system to control the number and action of T cells used in adoptive immunotherapy.
Conclusion: A reliable, safe, effective and collective platform can be established through further scientific and technical approaches in the clinic.
Although programmed death (PD) ‐1 immune checkpoint therapies target the immune system, the relationship between inflammatory factors and the clinical outcome of anti‐PD‐1 therapy for nonsmall cell lung cancer (NSCLC) is not fully understood. Here we examined the association between soluble immune mediators and the outcome of treatment with PD‐1 inhibitors in patients with advanced/recurrent NSCLC. In two independent cohorts, we assessed the levels of 88 different soluble immune mediators in peripheral blood before and after anti‐PD‐1 treatment, and evaluated their associations with clinical outcomes. In the tr...
Individuals with cancer are at a high risk of skeletal muscle wasting that may be exacerbated by tumour-related factors and cancer therapies (certain hormone and chemotherapies in particular) (Barreto et al., 2016; Vaughan et al., 2013; Aversa et al., 2017; Christensen et al., 2014; Shachar et al., 2016). An emerging body of literature supports the role of exercise as a means to ameliorate these treatment-related declines and improve clinically relevant outcomes in individuals with cancer (Schmitz et al., 2009; Galvao et al., 2010; Focht et al., 2018; Fairman et al., 2017a).